Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526224 | 0.72 | HSD17B10 (0.42) | HRH4KDM4EALDH1A1 | |
| SCHEMBL23236538 | 0.72 | GRIN1 (0.41) | HRH4GRIN1GRIN2BKCNH2 | |
| SCHEMBL33526642 | 0.71 | SCN9A (0.32) | SCN9A | |
| SCHEMBL33527018 | 0.71 | GRIN1 (0.34) | GRIN1GRIN2BPDE2APDE10ASCN9A | |
| SCHEMBL25635022 | 0.66 | HRH4 (0.32) | HRH4GRIN1GRIN2BCYP17A1CYP2C9 | |
| SCHEMBL27341169 | 0.65 | NPC1 (0.32) | HRH4GRIN1GRIN2BKDM4E | |
| SCHEMBL19231291 | 0.65 | PIK3CA (0.37) | GRIN1GRIN2BKCNH2MAT2A | |
| SCHEMBL14970148 | 0.65 | ADORA2A (0.49) | SYKPDE2APDE10ASCN9ACYP17A1 | |
| SCHEMBL557901 | 0.64 | SCN9A (0.57) | SYKSCN9A | |
| SCHEMBL24588076 | 0.63 | MBOAT4 (0.36) | HRH4GRIN1GRIN2BPDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | HRH4 211/4885GRIN1 1493/4885GRIN2B 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.